This issue PME talks to …
The BioIndustry Association CEO talks about the state of UK biotech, its shared ecosystem with the country’s pharmaceutical industry and the funding challenges biotech faces
And we take a look at …
Orphan diseases represent one of the most exciting and emotive areas in modern medicine and need a communications strategy that covers a spectrum of issues, say Dr Jonathan Morton and Dr Richard White of OxfordPharmagenesis
… South Korea: the ascendance of biobetters
Global pharma companies need to take the capabilities and experience of South Korean firms into consideration when developing their competitive strategies
… Masterclass: channel strategy
Channel strategy could be a significant stone unturned in the battle to win customers and patients, says David Watson of a MSI Consultancy
… Innovation: what to look out for in 2013
Context-based services and social media are among the major technology trends that pharma will need to embrace in the year ahead
… Pipeline: promising treatments for melanoma
The BREAK-2 phase II trial showed that dabrafenib 150mg twice daily had rapid onset of action, high response rates and prolonged progression-free survival
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
